Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, ...
WESTON, Fla., May 9, 2025 /PRNewswire/ - Apotex Corp. today launched IVRA™ (Melphalan) hydrochloride injection 90mg/ml multidose vial ("IVRA"), first ready-to-dilute liquid formulation of Melphalan ...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, ...
The product is supplied as a 90mg/mL multiple-dose vial for dilution. Ivra ™, a ready-to-dilute liquid formulation of melphalan, has been made available by Apotex. Ivra is an alkylating drug indicated ...
As of February 23 at 3:59:50 p.m. EST. Market Open.
, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For ...
At close: 23 February at 15:59:50 GMT-5 Chart does not reflect overnight price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results